{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:24:53Z","timestamp":1793395493581,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81702286, 82304408"],"award-info":[{"award-number":["81702286, 82304408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Youth Research Fund of Sichuan Tianfu Qingcheng Plan","award":["CZ2024010-5"],"award-info":[{"award-number":["CZ2024010-5"]}]},{"name":"the Research Project of Science and Technology Department of Sichuan Province","award":["2024NSFSC1738, 2025ZNSFSC0546, 2021YJ0134"],"award-info":[{"award-number":["2024NSFSC1738, 2025ZNSFSC0546, 2021YJ0134"]}]},{"name":"the Health Commission of Sichuan Province Medical Science and Technology Program","award":["24QNMP010"],"award-info":[{"award-number":["24QNMP010"]}]},{"name":"Chengdu Medical Research Project","award":["2024318"],"award-info":[{"award-number":["2024318"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01139-7","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:07:24Z","timestamp":1776841644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CZC54252 overcomes Osimertinib resistance by targeting EGFRC797S mutations"],"prefix":"10.1186","volume":"27","author":[{"given":"Tingnan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1139_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1139_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.lungcan.2006.08.015","volume":"54","author":"YK Jeon","year":"2006","unstructured":"Jeon YK, Sung S-W, Chung J-H, Park W-S, Seo J-W, Kim CW, et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer Amst Neth. 2006;54:387\u201398. https:\/\/doi.org\/10.1016\/j.lungcan.2006.08.015.","journal-title":"Lung Cancer Amst Neth"},{"key":"1139_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40265-022-01698-z","volume":"82","author":"MP Shah","year":"2022","unstructured":"Shah MP, Neal JW. Targeting acquired and intrinsic resistance mechanisms in epidermal growth factor receptor mutant non-small-cell lung cancer. Drugs. 2022;82:649\u201362. https:\/\/doi.org\/10.1007\/s40265-022-01698-z.","journal-title":"Drugs"},{"key":"1139_CR4","doi-asserted-by":"publisher","first-page":"90557","DOI":"10.18632\/oncotarget.21164","volume":"8","author":"J Xu","year":"2017","unstructured":"Xu J, Wang J, Zhang S. Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget. 2017;8:90557\u201378. https:\/\/doi.org\/10.18632\/oncotarget.21164.","journal-title":"Oncotarget"},{"key":"1139_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0337.","journal-title":"Cancer Discov"},{"key":"1139_CR6","doi-asserted-by":"publisher","unstructured":"Marquez-Medina D, Popat S. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future Oncol. 2015;11. https:\/\/doi.org\/10.2217\/fon.15.183.","DOI":"10.2217\/fon.15.183"},{"key":"1139_CR7","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.critrevonc.2024.104295","volume":"196","author":"A Ferro","year":"2024","unstructured":"Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, et al. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol. 2024;196:104295. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104295.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1139_CR8","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jtho.2017.10.027","volume":"13","author":"A Leone","year":"2018","unstructured":"Leone A. C797S and T790M EGFR mutations in non-small-cell lung cancer: In Trans or in separate clones?\u200b. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:e21\u20132. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.027.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1139_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jjco\/hyad052","volume":"53","author":"T Araki","year":"2023","unstructured":"Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023;53:547\u201361. https:\/\/doi.org\/10.1093\/jjco\/hyad052.","journal-title":"Jpn J Clin Oncol"},{"key":"1139_CR10","doi-asserted-by":"publisher","first-page":"104246","DOI":"10.1016\/j.critrevonc.2023.104246","volume":"194","author":"A Belloni","year":"2024","unstructured":"Belloni A, Pugnaloni A, Rippo MR, Di Valerio S, Giordani C, Procopio AD, et al. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review. Crit Rev Oncol Hematol. 2024;194:104246. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104246.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1139_CR11","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","volume":"29","author":"JB Blaquier","year":"2023","unstructured":"Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, Recondo G. Tackling osimertinib resistance in EGFR-mutant Non-Small-Cell Lung Cancer\u200b. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29:3579\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1912.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1139_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jtho.2023.11.016","volume":"19","author":"C Lu","year":"2024","unstructured":"Lu C, Wei X-W, Wang Z, Zhou Z, Liu Y-T, Zheng D, et al. Allelic context of EGFR C797X-mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2024;19:601\u201312. https:\/\/doi.org\/10.1016\/j.jtho.2023.11.016.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1139_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","volume":"19","author":"JK Rotow","year":"2024","unstructured":"Rotow JK, Lee JK, Madison RW, Oxnard GR, J\u00e4nne PA, Schrock AB. Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2024;19:227\u201339. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1453.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1139_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132. https:\/\/doi.org\/10.1038\/nm.3854.","journal-title":"Nat Med"},{"key":"1139_CR15","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, et al. Acquired resistance mechanisms to osimertinib: The constant battle. Cancer Treat Rev. 2023;116:102557. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102557.","journal-title":"Cancer Treat Rev"},{"key":"1139_CR16","doi-asserted-by":"publisher","first-page":"106057","DOI":"10.1016\/j.bioorg.2022.106057","volume":"128","author":"H-Y Zhao","year":"2022","unstructured":"Zhao H-Y, Xi X-X, Xin M, Zhang S-Q. Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs. Bioorg Chem. 2022;128:106057. https:\/\/doi.org\/10.1016\/j.bioorg.2022.106057.","journal-title":"Bioorg Chem"},{"key":"1139_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1021\/cb2002413","volume":"6","author":"N Ramsden","year":"2011","unstructured":"Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson\u2019s disease-related toxicity in human neurons. ACS Chem Biol. 2011;6:1021\u20138. https:\/\/doi.org\/10.1021\/cb2002413.","journal-title":"ACS Chem Biol"},{"issue":"Suppl 3","key":"1139_CR18","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","volume":"8","author":"NM Andrews Wright","year":"2019","unstructured":"Andrews Wright NM, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 3):S247\u201364. https:\/\/doi.org\/10.21037\/tlcr.2019.06.01.","journal-title":"Transl Lung Cancer Res"},{"key":"1139_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"1139_CR20","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"Y-L Wu","year":"2020","unstructured":"Wu Y-L, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer\u200b. N Engl J Med. 2020;383:1711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2027071.","journal-title":"N Engl J Med"},{"key":"1139_CR21","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","volume":"19","author":"K Kashima","year":"2020","unstructured":"Kashima K, Kawauchi H, Tanimura H, Tachibana Y, Chiba T, Torizawa T, et al. CH7233163 overcomes osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation\u200b. Mol Cancer Ther. 2020;19:2288\u201397. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0229.","journal-title":"Mol Cancer Ther"},{"key":"1139_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2020.12.028","volume":"153","author":"PL Chia","year":"2021","unstructured":"Chia PL, Parakh S, Russell P, Gan HK, Asadi K, Gebski V, et al. Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. Lung Cancer Amst Neth. 2021;153:35\u201341. https:\/\/doi.org\/10.1016\/j.lungcan.2020.12.028.","journal-title":"Lung Cancer Amst Neth"},{"key":"1139_CR23","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/pharmaceutics15082130","volume":"15","author":"J Bang","year":"2023","unstructured":"Bang J, Jun M, Lee S, Moon H, Ro SW. Targeting EGFR\/PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma. Pharmaceutics. 2023;15:2130. https:\/\/doi.org\/10.3390\/pharmaceutics15082130.","journal-title":"Pharmaceutics"},{"key":"1139_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140\u201356. https:\/\/doi.org\/10.1038\/nrd4204.","journal-title":"Nat Rev Drug Discov"},{"key":"1139_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c03655","author":"C Guo","year":"2026","unstructured":"Guo C, Wang X, Guan Q, Zhong S, Zhang L, Liu Y, et al. Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer. J Med Chem. 2026. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03655.","journal-title":"J Med Chem"},{"key":"1139_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12967-025-06613-0","volume":"23","author":"J Zhan","year":"2025","unstructured":"Zhan J, Xue J, Wu L, Zhang Z, Wang Q, Ma Y, et al. HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer. J Transl Med. 2025;23:628. https:\/\/doi.org\/10.1186\/s12967-025-06613-0.","journal-title":"J Transl Med"},{"key":"1139_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/cas.15229","volume":"113","author":"Y Liu","year":"2022","unstructured":"Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T, et al. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci. 2022;113:709\u201320. https:\/\/doi.org\/10.1111\/cas.15229.","journal-title":"Cancer Sci"},{"key":"1139_CR28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3720","author":"EJ Lee","year":"2026","unstructured":"Lee EJ, Ko JA, Kim M-J, Cho JS, Han J-Y, Kim SW, et al. JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. Clin Cancer Res Off J Am Assoc Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3720.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01139-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:13:49Z","timestamp":1780877629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01139-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01139-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves animal models. All animal experiments were conducted in accordance with relevant institutional, national, and international guidelines and regulations, including the ARRIVE guidelines and the guidelines of the International Council for Laboratory Animal Science (ICLAS). All animal studies were reviewed and approved by the Animal Care and Use Committee of Sichuan Academy of Medical Sciences and Sichuan Provincial People\u2019s Hospital (Approval No.: 2017110). All efforts were made to minimize animal suffering, and appropriate anesthesia and euthanasia procedures were performed in accordance with accepted veterinary standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}